Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03983824
Title Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
Los Angeles General Medical Center Los Angeles California 90033 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
USC Norris Oncology/Hematology-Newport Beach Newport Beach California 92663 United States Details
Keck Medical Center of USC Pasadena Pasadena California 91105 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables Florida 33146 United States Details
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach Florida 33442 United States Details
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136 United States Details
UM Sylvester Comprehensive Cancer Center at Plantation Plantation Florida 33324 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Mount Sinai Hospital New York New York 10029 United States Details
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field